Quest sells royalty rights to cancer drug ibrutinib for $485M

07/19/2013 | Genetic Engineering & Biotechnology News

Royalty Pharma agreed to pay $485 million in cash to acquire Quest Diagnostics' royalty rights from commercialization of ibrutinib, a drug candidate for chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma. The drug is being jointly developed by Pharmacyclics and Janssen Biotech. Quest obtained the royalty rights as part of its purchase of Celera in 2011.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA